Articles By Janet Pope, MD, MPH, FRCPC

CAR T on purple background

How many CAR-T’s do we need to test drive?

By Janet Pope, MD, MPH, FRCPC

CAR-T at #EULAR2026 raised as many questions as it answered. Here's what we know, what we're still asking, and why the answers matter.

Read Article
lupus SLE

How to treat SLE in 2026 and beyond!

By Janet Pope, MD, MPH, FRCPC

There are so many SLE trials, and over the last year, many new ideas have been suggested.

Read Article
change,future,lens,clarity

‘Strong’ treatment predictions in inflammatory myositis

By Janet Pope, MD, MPH, FRCPC

Presented at EULAR 2026 London, Brepocitinib dual TYK2/JAK1 inhibitor with successful Phase 3 VALOR trial demonstrating significant improvement in skin and muscle symptoms in dermatomyositis (DM).

Read Article
syringe, pill, DMARD, Treatment, therapy

What should head-to-head studies in inflammatory arthritis teach us?

By Janet Pope, MD, MPH, FRCPC

The multimillion dollar question for inflammatory arthritis prescriptions is: which drug should I use next?

Read Article
human figures on blue circle

IgG4: Rare, but new treatments on the horizon

By Janet Pope, MD, MPH, FRCPC

IgG4 is a rare autoimmune disease with excessive IgG4 immunoglobulins that can affect multiple organs yielding plasma cell deposition (inflammation) and fibrosis.

Read Article
Big data

Rheumatoid arthritis and the ‘big bang’ at the ACR!

By Janet Pope, MD, MPH, FRCPC

Is there ‘bang for the buck’ using big data to help predict who will develop RA in at-risk populations and similarly to predict response to csDMARDs, TNFi and JAKi in RA?

Read Article
magnifying glass with IPAF

What is IPAF?

By Janet Pope, MD, MPH, FRCPC

Idiopathic Interstitial Pneumonia with Autoimmune Features - or IPAF - describes patients with interstitial pneumonia with autoimmune features, but they don’t meet a diagnosis of a CTD.

Read Article
checklist on clipboard

How to assess ILD in your patients?

By Janet Pope, MD, MPH, FRCPC

Have a high index of suspicion in your patients with connective tissue disease (especially systemic sclerosis, inflammatory myositis), and rheumatoid arthritis.

Read Article
epilepsy,brain,seizure,CVA

Striking a ‘nerve’ in RA: understanding neuromodulation

By Janet Pope, MD, MPH, FRCPC

Over the last 50 years, discoveries of connections between inflammation and the nervous system have been better understood.

Read Article
steroids.prednisone.pills_.jpg

How to properly use steroids in early RA

By Janet Pope, MD, MPH, FRCPC

Guidelines differ on the early treatment of RA – ACR suggests not to use glucocorticoids (GC) and EULAR updated recommendations for RA treatment presented at #EULAR2025 continued to suggest early treatment with MTX and glucocorticoids. We do know that it is not easy to get a significant minority of RA patients off of prednisone.

Read Article
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

Profile picture for user Janet Pope, MD, MPH, FRCPC
  • Janet Pope, MD, MPH, FRCPC

  • Dr. Janet Pope is a Professor of Medicine in the Division of Rheumatology at the University of Western Ontario (UWO), Schulich School of Medicine, London, Ontario, Canada.  She is the Division Head in Rheumatology at St. Joseph's Health Centre, London. Her research includes studies in scleroderma, SLE and RA, including outcome measurements, clinical trials and disease manifestations. She has published over 450 peer-reviewed articles, 15 chapters, 500 abstracts and several Cochrane meta-analysis reviews. Mentoring of research students and trainees numbers more than 125. She has received the Distinguished Investigator Award from the Canadian Rheumatology Association, Rheumatologist of the Year from the Ontario Rheumatology Association, Department of Medicine Research Achievement Award, and the Dean’s Award of Excellence in Research. She has been inducted into the Canadian Academy of Health Sciences.

     

×